NEW YORK - Delcath Systems, Inc. (NASDAQ:DCTH), a company specializing in interventional oncology treatments, today announced the appointment of Martha S. Rook, Ph.D., as its new Chief Operating Officer (COO).
Dr. Rook is recognized for her extensive experience in molecular biology, diagnostics development, and biologics manufacturing, bringing over 25 years of academic and industry expertise to Delcath.
Prior to joining Delcath, Dr. Rook played a significant role at insitro as the Chief Technical Operations Officer, overseeing core research services, facilities, and laboratory operations. She has also held a pivotal position at Sigilon Therapeutics as Chief Technical Operations Officer, managing analytics, manufacturing, supply chain, and quality organizations for biologic-device combination products.
Delcath's CEO, Gerard Michel, expressed enthusiasm for Dr. Rook's addition to the leadership team, citing her deep understanding of the technical, business, and regulatory aspects of complex combination products. Her appointment is expected to be particularly beneficial as Delcath expands the production of its proprietary products, HEPZATO KIT and CHEMOSAT.
Dr. Rook's previous experience includes a 13-year tenure at MilliporeSigma, where she led the Gene Editing & Novel Modalities Business. She holds a Ph.D. in biochemistry from MIT and a B.S. in chemistry from Texas A&M University, with postdoctoral studies in neuroscience at Harvard Medical School's Center for Neurologic Diseases.
As part of her employment inducement, Delcath granted Dr. Rook an equity award to purchase 125,000 shares of the company's common stock, in compliance with NASDAQ Listing Rule 5635(c)(4). The options, granted on the day of her appointment, will vest over a 36-month period, contingent upon her continued service with the company.
Delcath specializes in treatments for primary and metastatic liver cancers, with products like HEPZATO KIT approved in the United States and CHEMOSAT designated for use in Europe and the United Kingdom. These products aim to deliver high-dose chemotherapy to the liver while minimizing systemic exposure and side effects.
This announcement is based on a press release statement from Delcath Systems, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.